Compugen (NASDAQ: CGEN) Navigates Q1 2026 Financials Amidst Clinical Progress

Font: Financial Modeling Prep  • May 18, 2026

• Compugen (NASDAQ: CGEN) reported a wider-than-expected Q1 2026 loss per share of -$0.08 and missed revenue estimates, posting $2.18 million.
• Despite mixed financials, the clinical-stage biopharmaceutical company is advancing its clinical programs, including the COM701 trial for ovarian cancer and a significant partnership with AstraZeneca (NASDAQ: AZN).
• The company maintains a strong financial position with sufficient cash to fund operations into 2029, supported by a low debt-to-equity ratio of 0.03 and a healthy current ratio of 6.56.

Compugen (NASDAQ: CGEN) is a clinical-stage biopharmaceutical company that develops new therapies for cancer immunotherapy. It focuses on discovering and developing drugs that use the body's immune system to fight cancer. The company often partners with larger pharmaceutical firms, such as AstraZeneca (NASDAQ: AZN) and Gilead (NASDAQ: GILD), to advance its potential treatments through clinical trials.

On May 18, 2026, Compugen reported its first-quarter 2026 financial results. The company posted a loss per share of -$0.08. This figure was slightly wider than the consensus analyst estimate of a -$0.07 loss per share. As highlighted by Zacks, this loss is consistent with the -$0.08 per share loss reported in the same quarter of the previous year, reflecting ongoing investment in its drug development pipeline.

For the quarter, Compugen’s revenue was $2.18 million. This amount missed the consensus estimate and was a decrease from the $2.28 million reported a year ago. Over the last four quarters, Compugen has managed to surpass consensus earnings per share estimates two times, showing a mixed history of meeting market expectations in its quarterly revenue performance.

Despite the mixed financial report, the company shows progress in its clinical programs. As reported by PR Newswire, its COM701 trial for ovarian cancer is actively enrolling patients. Additionally, its partnership with AstraZeneca is advancing a drug called rilvegostomig across eleven different late-stage trials, with new data expected to be presented soon, highlighting its robust clinical development pipeline.

Compugen maintains a solid financial position with enough cash to fund its operations into 2029. The company's balance sheet appears healthy, with a low debt-to-equity ratio of 0.03. It also has a current ratio of 6.56, which indicates it has more than enough short-term assets to cover its short-term liabilities, underscoring its financial health and liquidity.